Thrombophilia and Thrombosis in Behçet's Disease

Thrombophilia and Tendency to Thrombosis in Behçet's Disease

Behçet's disease (BD) is a systemic vasculitis of unknown cause, affecting mainly young adults. Vasculopathy has been reported in 16.8-51.5% of cases. Genetic, infectious factors, environmental factors, presence of autoantibodies, endothelial pathologies and hypercoagulability are responsible for the etiopathogenesis of BD. The main involvements responsible for morbidity and mortality in Behçet's disease are ocular, major cardiovascular and neurological involvements. Although there is an increased thrombotic risk in the etiopathogenesis of Behçet's disease, the cellular and molecular mechanisms are not fully understood. Although endothelial dysfunction due to inflammation has been shown to be the primary cause of vascular damage in Behçet's disease, some clinical evidence suggests that hypercoagulable states also contribute to thrombosis. The most common form of vascular involvement in Behçet's disease is deep vein thrombosis in the lower extremities. Arterial occlusion mostly affects the subclavian and pulmonary arteries. Although arterial involvement is rarer than venous involvement in Behçet's disease, morbidity and mortality are higher than venous involvement.

Although an increased thrombotic risk is mentioned in the etiopathogenesis of Behçet's disease, it is still controversial whether vasculitis or susceptibility to hypercoagulability plays a role in the pathogenesis of venous thrombosis. In addition, there are very few studies in the literature in which all thrombophilic parameters were analysed. Again, there is no recent study on this subject. The aim of our study is to determine the risk of hypercoagulability in Behçet's disease patients with vascular involvement, which has a highly mortal course.

Study Overview

• Status: Recruiting
• Conditions: Behçet Disease
• Intervention / Treatment: Diagnostic test: Blood collection

Detailed Description

The study was planned as a prospective case control study. The study will be conducted on 100 Behçet's patients aged 18-70 years who were diagnosed with Behçet's disease according to the International Behçet's diagnostic criteria and 100 healthy controls similar in age and gender who applied to Atatürk University Faculty of Medicine Dermatology outpatient clinic between June 2023 and September 2024. Routine clinical evaluations of all patients will be performed. Demographic characteristics (age, gender), clinical features of the disease and medications used will be recorded. Patients will be included in the study after the relevant department consultations for system involvement. Skin and mucous membrane findings seen in the last 1 month will be recorded. Blood samples will be taken from all participants and analysed in the Genetics laboratory of our hospital. DNA isolation will be performed with DNA isolation kit from peripheral blood in EDTA tube taken from patients during routine examinations. DNA samples will be stored at -20 degrees Celsius until the time of the study. After collecting the targeted number of samples, Factor II G20210A, Factor V Leiden G1691A, MTHFR (Methylene Tetra Hydro Folate Reductase) C677T, MTHFR A1298C, Factor XIII V34L, PAI (Plasminogen Activator Inhibitor-1) 4G/5G SNP (single nucleotide polymorphisms) analyses will be performed with the thrombophilia panel kit. This analysis will be performed by fragment analysis method on the ABI 3130 Genetic analyser device in the Medical Genetics Laboratory. Firstly, PCR study will be performed with the thrombophilia panel kit, the plate with patient DNA will be loaded into the capillary electrophoresis device and the analyses will be interpreted and finalised with GeneMapper software.

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

• Study Contact: Name: ERDAL PALA; Phone Number: +95383753661; Email: erdal.pala@atauni.edu.tr

Study Locations

• Turkey
  • Üniversite Mahallesi
    • Erzurum, Üniversite Mahallesi, Turkey, 25240
      • Recruiting
      • Erdal Pala
      • Contact: ERDAL PALA; Phone Number: +95383753661; Email: erdalpala2525@gmail.com
      • Sub-Investigator: Zeynep karaca Ural
      • Sub-Investigator: Çiğdem Yüca Kahraman
      • Sub-Investigator: Ümit Arslan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

100 patients with Behçet's disease aged 18-70 years and 100 age- and sex-matched healthy controls

Description

Inclusion Criteria:

1. 18-70 years old
2. Patients who fulfil the international diagnostic criteria for Behçet's disease
3. Those who accepted the consent form

Exclusion Criteria:

1. Those under 18 years of age
2. accompanied by another inflammatory dermatological disease
3. Pregnancy and breastfeeding
4. Those who use drugs that increase the tendency to thrombosis -

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cases with Behcet's disease; Behcet's disease	Diagnostic test: Blood collection; Blood collection
healthy individuals; Healthy control group	Diagnostic test: Blood collection; Blood collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Faktor II G20210A kit	Faktor II G20210A at 200 participants	15 months
Faktor V Leiden kit	Faktor V Leiden at 200 participants	15 months
G1691A kit	G1691A at 200 participants	15 months
MTHFR (Methylene Tetra Hydro Folate Reductase) kit	MTHFR (Methylene Tetra Hydro Folate Reductase) at 200 participants	15 months
C677T kit	C677T at 200 participants	15 months
Factor XIII kit	Factor XIII at 200 participants	15 months
With DNA isolation kit	PAI (Plasminogen Activator Inhibitor-1) at 200 participants	15 months

Collaborators and Investigators

• Sponsor: Ataturk University
• Investigators: Principal Investigator: ERDAL PALA, Ataturk University

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2023
• Primary Completion (Estimated): September 1, 2024
• Study Completion (Estimated): September 1, 2024

Study Registration Dates

• First Submitted: May 23, 2024
• First Submitted That Met QC Criteria: June 4, 2024
• First Posted (Actual): June 11, 2024

Study Record Updates

• Last Update Posted (Actual): June 11, 2024
• Last Update Submitted That Met QC Criteria: June 4, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Keywords: thrombosis; Behcet's disease; thrombophilia
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Skin Diseases; Eye Diseases; Hematologic Diseases; Genetic Diseases, Inborn; Stomatognathic Diseases; Mouth Diseases; Embolism and Thrombosis; Uveitis, Anterior; Panuveitis; Uveitis; Uveal Diseases; Vasculitis; Hereditary Autoinflammatory Diseases; Skin Diseases, Genetic; Skin Diseases, Vascular; Behcet Syndrome; Thrombosis; Thrombophilia
• Other Study ID Numbers: 30.03.2023/219

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No